Gastric Motility Disorder Drugs Market
Number of pages: 100 | Report Format: PDF | Published date: June 23, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
3.5% |
|
Base Year For Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Route of Administration, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global gastric motility disorder drugs market is expected to register a revenue CAGR of 3.5% during the predicted timeframe from 2023 to 2031.
Gastric Motility Disorder Drugs Market Fundamentals
Gastric motility disorders refer to a group of conditions that affect the normal movement and function of the muscles in the stomach. These disorders can disrupt normal digestion and emptying of food from the stomach into the small intestine. Heartburn, regurgitation, choking, gastrointestinal discomfort, diarrhea, and constipation are some of the symptoms. Cholinergic agonists, prokinetic drugs, opioid antagonists, antidiarrheals, and antibiotics are among the common medications used to treat intestinal motility problems. The most effective drugs for treating these illnesses include neostigmine, bethanechol, metoclopramide, cisapride, and loperamide.
Gastric Motility Disorder Drugs Market Dynamics
Gastric motility disorders, such as gastroparesis, are becoming more prevalent. According to NIH report, it was noticed that out of 100,000 people, about 10 men and about 40 women suffer from gastroparesis. The rising incidence of conditions such as diabetes, which can contribute to the development of gastric motility disorders, is driving the demand for effective treatment options. Advances in drug delivery systems and formulations are enhancing the treatment options available for gastric motility disorders. Improved drug delivery methods, such as extended-release formulations or targeted delivery systems, can optimize drug efficacy and patient compliance. For instance, in June 2020, Evoke Pharma, Inc. received the the New Drug Application (NDA) approval for GIMOTI (metoclopramide) nasal spray, the first and only nasally-administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. There is ongoing research and development in the field of gastric motility disorder drugs, with several pharmaceutical companies investing in developing novel therapeutic options. This includes exploring new drug classes and mechanisms of action to address the underlying causes of gastric motility disorders. For instance, the U.S. Food and Drug Administration gave the green light to Dupixent (dupilumab) for the eosinophilic esophagitis (EoE) treatment in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds). As awareness about gastric motility disorders grows, more patients seek medical attention and get diagnosed. This increased recognition of the condition will likely drive the demand for drugs targeting gastric motility disorders. Despite the available treatment options, there is still an unmet need for more effective and well-tolerated drugs for gastric motility disorders. This creates opportunities for pharmaceutical companies to develop innovative therapies that can provide better symptom relief and improved quality of life for patients. Renexxion Ireland Limited announced the opening of an investigational new drug application (IND) with the FDA in January 2023. It is seeking approval to evaluate the use of naronapride for treating gastrointestinal motility disorders in patients with cystic fibrosis. Regulatory bodies play a crucial role in drug approval and market access for gastric motility disorders. The evolving regulatory landscape and the guidance regulatory agencies provide influence the development and commercialization of new drugs in this field.
Diagnosing gastric motility disorders can be challenging due to the wide range of symptoms and the need for specialized tests. Misdiagnosis or delayed diagnosis can lead to inappropriate or ineffective treatments. Gastric motility disorders encompass a range of conditions with varying underlying causes and symptom presentations. Such patient heterogeneity makes it difficult to develop standardized treatment approaches, and personalized medicine tailored to individual patients' needs is often required. Some medications used to manage gastric motility disorders can have significant side effects. For example, prokinetic agents that stimulate stomach contractions may cause adverse effects such as diarrhea, nausea, and neurological complications. Balancing the benefits and risks of pharmacological treatments is a challenge in this field. Moreover, the complex nature of these disorders, coupled with the need for rigorous clinical trials and regulatory approvals, increases the financial burden on pharmaceutical companies, which may limit investment in research and development.
Gastric Motility Disorder Drugs Market Ecosystem
The global gastric motility disorder drugs market has been analyzed from the following perspectives: drug class, route of administration, distribution channel, and region.
Gastric Motility Disorder Drugs Market by Drug Class
Based on the drug class, the global gastric motility disorder drugs market is segmented into cholinergic agonists, prokinetic agents, opioid antagonists, antidiarrheals, and antibiotics.
Cholinergic agonists account for a notable revenue share in the global market. Cholinergic agonists work by activating cholinergic receptors in the gastrointestinal tract, promoting the release of acetylcholine, a neurotransmitter that enhances gastrointestinal motility. These drugs help stimulate smooth muscle contractions in the stomach and promote gastric emptying. Medications such as metoclopramide and domperidone, which have cholinergic properties, are commonly prescribed for treating gastroparesis and other motility disorders. The long history of use and familiarity with these drugs contribute to their dominant position in the market. Cholinergic agonists have demonstrated efficacy in improving gastric emptying and alleviating symptoms associated with gastric motility disorders. They can help reduce symptoms such as nausea, vomiting, and bloating by facilitating food movement through the digestive system. The effectiveness of these drugs in managing symptoms contributes to their widespread use and dominance in the market.
Despite ongoing research and development efforts, limited alternatives are available for efficiently treating gastric motility disorders. While other drug classes and treatments are being explored, cholinergic agonists remain the most established and widely prescribed option.
Gastric Motility Disorder Drugs Market by Route of Administration
Based on the route of administration, the global gastric motility disorder drugs market is segmented into oral, subcutaneous, intramuscular, intravenous, and others.
Oral administration dominates the global market, as this allows self-administration at home, improving convenience and compliance. The oral route of administration has been widely accepted and preferred by both healthcare providers and patients. It is a well-established method with a long history of use for drug delivery. Oral drug administration comes with various formulation options, including tablets, capsules, liquids, and orally disintegrating tablets. Additionally, the availability of multiple oral formulations contributes to the dominance of this route in the market. The oral route is generally considered safe and well-tolerated, with a lower risk of complications than invasive routes. It also tends to be a cost-effective method of drug administration, both for pharmaceutical manufacturers and healthcare systems. Oral medications can be produced at a lower cost and do not require specialized equipment or healthcare professionals for administration, which contributes to their dominance in the market. The regulatory approval process for oral medications is well-established and generally faster than other administration routes.
Gastric Motility Disorder Drugs Market by Distribution Channel
Based on the distribution channels, the global gastric motility disorder drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Hospitals often have pharmacies to dispense medications to inpatients and outpatients. Therefore, hospital pharmacies may have a significant role in providing these medications to patients who receive treatment within the hospital setting. Some hospitals or healthcare centers have specialized gastroenterology departments or motility centers that focus on diagnosing and treating gastric motility disorders. In a hospital setting, there may be better coordination among the specialists, leading to prescriptions being filled and dispensed through hospital pharmacies for streamlined patient care. Compounded medications, which are custom-made formulations tailored to individual patient’s needs, may be required for certain cases of gastric motility disorders. Hospital pharmacies often have the capabilities and expertise to compound medications, allowing them to meet specific patient requirements.
Gastric Motility Disorder Drugs Market by Region
Based on the region, the global gastric motility disorder drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America accounts for the largest revenue share in the global market. North America has a highly developed healthcare infrastructure with advanced medical facilities, research institutions, and specialized centers on gastrointestinal disorders. This infrastructure supports diagnosing, treating, and researching gastric motility disorders, leading to a higher demand for related medications. Gastric motility disorders like gastroparesis are relatively common in North America. Factors such as the aging population, increasing incidence of conditions like diabetes (which can contribute to gastric motility disorders), and improved diagnostic techniques contribute to higher prevalence and diagnosis rates in the region. As a result, medications are more needed to manage these conditions. North America has a robust pharmaceutical industry, with many leading companies researching and developing gastrointestinal disorders, including gastric motility disorders. This contributes to the development of new drugs, treatment options, and therapeutic advancements that drive the region's market growth. For instance, in April 2022, Ardelyx, Inc. launched its product called ‘IBSRELA’, the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. The healthcare systems in North America, particularly in the United States and Canada, typically provide better access to healthcare services and medication reimbursement. This facilitates patient access to gastric motility disorder drugs and encourages market growth. North America has well-established regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and Health Canada, which provide clear guidelines for drug development, approval, and market access. The stringent yet predictable regulatory environment supports the launch of new drugs and ensures patient safety, making North America an attractive market for pharmaceutical companies. Awareness about gastric motility disorders among healthcare professionals and the general population is relatively high in North America. This results in more proactive screening, diagnosis, and treatment of these conditions, driving the demand for related medications.
Competitive Landscape
The prominent players operating in the global gastric motility disorder drugs market are:
Gastric motility disorders refer to a group of conditions that affect the normal movement and function of the muscles in the stomach. These disorders can disrupt normal digestion and emptying of food from the stomach into the small intestine.
Lannett Company Inc., Novartis AG, Pfizer Inc., and Janssen Pharmaceuticals Inc. are major market players in the global gastric motility disorder drugs market.
The high cost of drug development, strict regulations, and technological challenges are some of the restraints obstructing the growth of the global market.
The hospital pharmacies segment dominates the global gastric motility disorder drugs market.
The growing prevalence of gastric motility disorders and increasing research and development activities are some of the major factors driving the global market.
*Insights on financial performance are subject to the availability of information in the public domain